A prospective randomized trial of enteral glutamine in critical illness
- 324 Downloads
To assess the influence of enteral glutamine on the incidence of severe sepsis and death in critically ill patients.
This two-armed clinical trial was triple blind (patients, attending staff, research nurse).
The 10 bed general ICU at Royal Perth Hospital, Western Australia.
This trial evaluated 363 patients requiring mechanical ventilation (median APACHE II score=14); of these, 85 had trauma.
The intervention solution contained 20 g/l glutamine and the control solution was isojoulic and isonitrogenous.
Measurements and results
The groups had similar characteristics at baseline, and they also received equivalent amounts of protein and energy. Patients in the glutamine group received a median of 19 g/glutamine per day and 91% (332 of 363) of the patients were fed via a nasogastric tube (median duration=10 days). The outcomes were similar in the two groups: (a) death within 6 months: glutamine group 15% (27 of 179) vs control group 16% (30 of 184); p=0.75; relative risk, 0.95 (95% confidence interval, 0.71–1.28); and (b) severe sepsis: glutamine group 21% (38 of 179) vs control group 23% (43 of 184); p=0.62; relative risk, 0.94 (95% confidence interval, 0.72–1.22). There was also no discernable difference in the secondary outcomes relating to infections, febrile period, antimicrobial therapy, and consumption of inotropes.
This clinical trial did not support the use of enteral glutamine supplements in similar cohorts of critically ill patients.
KeywordsEnteral nutrition Glutamine Critical illness Trauma Sepsis
Acknowledgements. This study was funded by the National Health and Medical Research Council of Australia. The authors thank the ICU staff at Royal Perth Hospital for facilitating the performance of this study. We are particularly indebted to the staff of the Feed Preparation Room at Royal Perth Hospital for their generous support of this clinical trial.
- 3.Karinch AM, Pan M, Lin CM, Strange R, Souba WW (2001) Glutamine metabolism in sepsis and infection. J Nutr 131 (Suppl):2535–2538Google Scholar
- 4.McCauley R, Kong S-E, Hall JC (1998) Glutamine and nucleotide metabolism within enterocytes. JPEN 22:105–111Google Scholar
- 5.Wilmore DW (2001) The effect of glutamine supplementation in patients following elective surgery and accidental injury. J Nutr 131 (Suppl):2543–2549Google Scholar
- 7.Platell C, McCauley R, McCulloch R, Hall JC (1993) The influence of parenteral glutamine and branched-chain amino acids on total parenteral nutrition-induced atrophy of the gut. JPEN 17:348–354Google Scholar
- 9.Gianotti L, Alexander JW, Gennari R, Pyles T, Babcock GF (1995) Oral glutamine decreases bacterial translocation and improves survival in experimental gut-origin sepsis. JPEN 19:69–74Google Scholar
- 21.Schwartz D, Lellouch J (1967) Explanatory and pragmatic attitudes in trials. J Chron Dis 210:637–648Google Scholar
- 24.Wischmeyer PE, Wischmeyer PE, Lynch J, Liedel J, Wolfson R, Riehm J, Gottlieb L, Kahana M (2001) Glutamine administration reduces Gram-negative bacteremia in severely burned patients: a prospective, randomized, double-blind trial versus isonitrogenous control. Crit Care Med 29:2075–2080PubMedGoogle Scholar
- 27.Conejero R, Bonet A, Grau T et al. (2002) Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically ill patients with systemic inflammatory response syndrome: a randomized, single-blind, prospective, multicenter study. Nutrition 18:716–721CrossRefPubMedGoogle Scholar
- 37.Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ (1999) Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785–792Google Scholar
- 39.Hall JC (1998) Glycine. JPEN 22:393–398Google Scholar
- 41.Lee MA, McCauley RD, Kong SE, Hall JC (2002) Influence of glycine on intestinal ischemia-reperfusion injury. JPEN 26:130–135Google Scholar